UBS Group
BIOS

UBS Group’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

UBS Group’s Portfolio BIOS Stock Details BIOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,828
Closed -$19.5K – 10229
2023
Q2 		$19.5K Buy
+1,828
New +$19.2K ﹤0.01% 6881
2023
Q1 		– Sell
-1,160
Closed -$11.9K – 11030
2022
Q4 		$11.9K Sell
1,160
-23,090
-95% -$234K ﹤0.01% 8342
2022
Q3 		$243K Sell
24,250
-500
-2% -$5K ﹤0.01% 4917
2022
Q2 		$247K Sell
24,750
-250
-1% -$2.48K ﹤0.01% 4755
2022
Q1 		$247K Buy
+25,000
New +$247K ﹤0.01% 5199

Other funds holding BIOS

WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

UBS Group's BIOS Position: Q3 2023 in Review

UBS Group sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q3 2023, closing a stake of 1,828 shares — an estimated $19.5K sold.

UBS Group first reported a position in BIOS in Q1 2022 and held it in 5 quarters. The position peaked at $247K in Q2 2022. 30 funds tracked by Wall St. Rank hold BIOS as of Q3 2023.

  • UBS Group reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • UBS Group sold 1,828 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q3 2023, an estimated $19.5K.
  • UBS Group first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 5 quarters.
  • UBS Group's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $247K in Q2 2022.
  • 30 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.